Drugs

, Volume 68, Issue 8, pp 1089–1103 | Cite as

Improving Delivery of Aminosalicylates in Ulcerative Colitis

Effect on Patient Outcomes
Review Article

Abstract

Developments in drug delivery technology have expanded the formulations of 5-aminosalicylic acid (5-ASA) available to clinicians over the last 50 years. Delivery of adequate doses of 5-ASA to the colon can be achieved by pH-dependent, delayed-release or pro-drug formulations. Despite some variations in the pharmacokinetics between individual preparations, the clinical effects in induction of response and maintenance of remission in ulcerative colitis appear to be consistent. Direct comparison studies between different preparations haveyielded similar results in primary endpoints, although differences in secondary endpoints or post hoc analyses have been noted. The development of delivery methods that allow once-daily administration represents a potential means to improve the low medication adherence rates reported in patients with ulcerative colitis.

Keywords

Ulcerative Colitis Sulfasalazine Mesalazine Active Ulcerative Colitis Balsalazide 

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Moss has received grant support from Protor & Gamble. Dr Fernandez-Becker has no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Goldman P, Peppercorn MA. Drug therapy: sulfasalazine. N Engl J Med 1975; 293: 20–3PubMedGoogle Scholar
  2. 2.
    Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis: B. Therapeutic results in ulcerative colitis: C. Toxic manifestations in treatments with sulfanilamide preparation. Acta Medica Scandinavia 1942; 110: 557–90Google Scholar
  3. 3.
    Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; I: 1094–6Google Scholar
  4. 4.
    Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; II: 892–5Google Scholar
  5. 5.
    van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632–5PubMedGoogle Scholar
  6. 6.
    Klotz U, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N Engl J Med 1980; 303: 1499–502PubMedGoogle Scholar
  7. 7.
    Hoult JR. Pharmacological and biochemical actions of sulphasalazine. Drugs 1986; 32 Suppl. 1: 18–26PubMedGoogle Scholar
  8. 8.
    Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972; 181: 555–62PubMedGoogle Scholar
  9. 9.
    Schroder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539–51PubMedGoogle Scholar
  10. 10.
    Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491–5PubMedGoogle Scholar
  11. 11.
    Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci 1983; 28: 833–42PubMedGoogle Scholar
  12. 12.
    Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther 2004; 19: 1089–98PubMedGoogle Scholar
  13. 13.
    MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000; 95: 3343–5PubMedGoogle Scholar
  14. 14.
    Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272: 399–406PubMedGoogle Scholar
  15. 15.
    Greenfield SM, Hamblin AS, Shakoor ZS, et al. Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine. Gut 1993; 34: 252–6PubMedGoogle Scholar
  16. 16.
    Axelsson LG, Ahlstedt S. Characteristics of immune-complex-induced chronic experimental colitis in rats with a therapeutic effect of sulphasalazine. Scand J Gastroenterol 1990; 25: 203–9PubMedGoogle Scholar
  17. 17.
    MacDermott RP, Schloemann SR, Bertovich MJ, et al. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989; 96: 442–8PubMedGoogle Scholar
  18. 18.
    Neal TM, Winterbourn CC, Vissers MC. Inhibition of neutrophil degranulation and Superoxide production by sulfasalazine: comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine. Biochem Pharmacol 1987; 36: 2765–8PubMedGoogle Scholar
  19. 19.
    Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn’s disease. Drugs 1999; 57: 383–408PubMedGoogle Scholar
  20. 20.
    Cominelli FZCA, Dinarello CA. Sulfasalazine inhibits cytokine production in human mononuclear cells: a novel anti-inflammatory mechanism. Gastroenterology 1992; 96: A96Google Scholar
  21. 21.
    Mahida YR, Lamming CE, Gallagher A, et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50–4PubMedGoogle Scholar
  22. 22.
    Rachmilewitz D, Karmeli F, Schwartz LW, et al. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992; 33: 929–32PubMedGoogle Scholar
  23. 23.
    Shanahan F, Niederlehner A, Carramanzana N, et al. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990; 20: 217–24PubMedGoogle Scholar
  24. 24.
    Collier HO, Francis AA, McDonald-Gibson WJ, et al. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins 1976; 11: 219–25PubMedGoogle Scholar
  25. 25.
    Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638–40PubMedGoogle Scholar
  26. 26.
    Gertner DJ, Rampton DS, de Nucci G, et al. Eicosanoid release by rectal mucosa in vitro in ulcerative colitis: effects of conventional and potential new therapies. European J Gastroenterol hepatol 1992; 4: 837–41Google Scholar
  27. 27.
    Horn H, Preclik G, Stange EF, et al. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes. Scand J Gastroenterol 1991; 26: 867–79PubMedGoogle Scholar
  28. 28.
    Schmidt C, Fels T, Baumeister B, et al. The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells. Curr Med Res Opin 1996; 13: 417–25PubMedGoogle Scholar
  29. 29.
    Dubuquoy L, Rousseaux C, Thuru X, et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55: 1341–9PubMedGoogle Scholar
  30. 30.
    Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163–74PubMedGoogle Scholar
  31. 31.
    Gionchetti P, Guarnieri C, Campieri M, et al. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on Superoxide radical generation. Dig Dis Sci 1991; 36: 174–8PubMedGoogle Scholar
  32. 32.
    Greenfield SM, Punchard NA, Thompson RP. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid. Gut 1991; 32: 1156–9PubMedGoogle Scholar
  33. 33.
    Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol 2002; 97: 2939–41PubMedGoogle Scholar
  34. 34.
    Sandborn WJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord 2006; 6: 97–105PubMedGoogle Scholar
  35. 35.
    Forbes A, Al-Damluji A, Ashworth S, et al. Multicentre randomized-controlled clinical trial of Ipocol, a new entericcoated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 1099–104PubMedGoogle Scholar
  36. 36.
    Marakhouski Y, Fixa B, Holoman J, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 133–40PubMedGoogle Scholar
  37. 37.
    Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4: 523–33PubMedGoogle Scholar
  38. 38.
    Hanauer SB, Sparrow M. Therapy of ulcerative colitis. Curr Opin Gastroenterol 2004; 20: 345–50PubMedGoogle Scholar
  39. 39.
    Ewe K, Schwartz S, Petersen S, et al. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci 1999; 44: 1434–9PubMedGoogle Scholar
  40. 40.
    Fallingborg J, Christensen LA, Ingeman-Nielsen M, et al. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989; 3: 605–13PubMedGoogle Scholar
  41. 41.
    Nugent SG, Kumar D, Rampton DS, et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001; 48: 571–7PubMedGoogle Scholar
  42. 42.
    Nugent SG, Kumar D, Rampton DS, et al. Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA containing capsules [abstract]. Gut 1999; 47Google Scholar
  43. 43.
    Press AG, Hauptmann IA, Hauptmann L, et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1998; 12: 673–8PubMedGoogle Scholar
  44. 44.
    Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66–75; quiz 432-3PubMedGoogle Scholar
  45. 45.
    Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95–102PubMedGoogle Scholar
  46. 46.
    Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108: 1427–33PubMedGoogle Scholar
  47. 47.
    Larouche J, Morais J, Picard M, et al. Release of 5-ASA from Pentasa in patients with Crohn’s disease of the small intestine. Aliment Pharmacol Ther 1995; 9: 315–20PubMedGoogle Scholar
  48. 48.
    Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs 2002; 62: 1689–705PubMedGoogle Scholar
  49. 49.
    Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 1989; 30: 1354–61PubMedGoogle Scholar
  50. 50.
    Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835–7PubMedGoogle Scholar
  51. 51.
    Kruis W, Brandes JW, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 707–15PubMedGoogle Scholar
  52. 52.
    Travis SP, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282–6PubMedGoogle Scholar
  53. 53.
    van Hees PA, Tuinte JH, van Rossum JM, et al. Influence of intestinal transit time on azo-reduction of salicylazosul-phapyridine (Salazopyrin). Gut 1979; 20: 300–4PubMedGoogle Scholar
  54. 54.
    Houston JB, Day J, Walker J. Azo reduction of sulphasalazine in healthy volunteers. Br J Clin Pharmacol 1982; 14: 395–8PubMedGoogle Scholar
  55. 55.
    Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628–36PubMedGoogle Scholar
  56. 56.
    Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13: 381–8PubMedGoogle Scholar
  57. 57.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317: 1625–9PubMedGoogle Scholar
  58. 58.
    Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 1991; 115: 350–5PubMedGoogle Scholar
  59. 59.
    Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669–74PubMedGoogle Scholar
  60. 60.
    Dew MJ, Hughes P, Harries AD, et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid [letter]. BMJ (Clin Res Ed) 1982; 285: 1012Google Scholar
  61. 61.
    Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. BMJ (Clin Res Ed) 1983; 287: 23–4Google Scholar
  62. 62.
    Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383–9PubMedGoogle Scholar
  63. 63.
    The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 204–11Google Scholar
  64. 64.
    Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 1111–9PubMedGoogle Scholar
  65. 65.
    Riley SA, Tavares IA, Bennett A, et al. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol 1988; 26: 173–7PubMedGoogle Scholar
  66. 66.
    Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188–97Google Scholar
  67. 67.
    Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 1995; 30 Suppl. 8: 108–11PubMedGoogle Scholar
  68. 68.
    Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995; 40: 296–304Google Scholar
  69. 69.
    Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95: 1449–53PubMedGoogle Scholar
  70. 70.
    Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol 1995; 7: 1025–30Google Scholar
  71. 71.
    Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 1398–407PubMedGoogle Scholar
  72. 72.
    Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998; 114: 15–22Google Scholar
  73. 73.
    Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 3078–86PubMedGoogle Scholar
  74. 74.
    Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges? Am J Gastroenterol 2002; 97: 1283–5PubMedGoogle Scholar
  75. 75.
    Selby WS, Barr GD, Ireland A, et al. Olsalazine in active ulcerative colitis. BMJ (Clin Res Ed) 1985; 291: 1373–5Google Scholar
  76. 76.
    Hetzel DJ, Shearman DJ, Labrooy J, et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scand J Gastroenterol Suppl 1988; 148: 61–9PubMedGoogle Scholar
  77. 77.
    Sutherland LR. Maintenance therapy for inflammatory bowel disease: what really works. Can J Gastroenterol 1997; 11: 261–4PubMedGoogle Scholar
  78. 78.
    Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65–78Google Scholar
  79. 79.
    Courtney MG, Nunes DP, Bergin CF, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992; 339: 1279–81PubMedGoogle Scholar
  80. 80.
    Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol 1988; 10: 406–9PubMedGoogle Scholar
  81. 81.
    Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991; 32: 929–31PubMedGoogle Scholar
  82. 82.
    Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; II: 270–1Google Scholar
  83. 83.
    Friedman LS, Richter JM, Kirkham SE, et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol 1986; 81: 412–8PubMedGoogle Scholar
  84. 84.
    Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000; 95: 1749–54PubMedGoogle Scholar
  85. 85.
    Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997; 11: 1053–7PubMedGoogle Scholar
  86. 86.
    Campieri M, Paoluzi P, D’Albasio G, et al. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: a multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993; 38: 1843–50PubMedGoogle Scholar
  87. 87.
    Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867–71PubMedGoogle Scholar
  88. 88.
    Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94: 1075–9PubMedGoogle Scholar
  89. 89.
    Biddle WL, Miner Jr PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990; 99: 113–8PubMedGoogle Scholar
  90. 90.
    d’Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143–7PubMedGoogle Scholar
  91. 91.
    D’Arienzo A, Panarese A, D’Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990; 85: 1079–82PubMedGoogle Scholar
  92. 92.
    Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115–20PubMedGoogle Scholar
  93. 93.
    De Vos M, Verdievel H, Schoonjans R, et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992; 33: 1338–42PubMedGoogle Scholar
  94. 94.
    Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (3): CD000543Google Scholar
  95. 95.
    Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478–85PubMedGoogle Scholar
  96. 96.
    Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5g twice daily) and mesalazine (0.5g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0g twice daily) was superior in preventing relapses. Gut 2001; 49: 783–9PubMedGoogle Scholar
  97. 97.
    Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007; 6: 99–107PubMedGoogle Scholar
  98. 98.
    Kles KAVS, Turner JR, Musch MW, et al. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine and mesalamine in rabbit distal ileum. Inflamm Bowel Dis 2005; 11: 253–7PubMedGoogle Scholar
  99. 99.
    Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol 1990; 12: 198–9PubMedGoogle Scholar
  100. 100.
    Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929–33PubMedGoogle Scholar
  101. 101.
    Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39–43PubMedGoogle Scholar
  102. 102.
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191–8PubMedGoogle Scholar
  103. 103.
    Hanauer S, Barish C, Pambianco D, et al. A multi-center double-blind placebo-controlled dose ranging trial of olsalazine for mild-moderately active ulcerative colitis [abstract]. Gastroenterology 1996; 110: A921Google Scholar
  104. 104.
    Robinson M, Gitnick G, Balart L, et al. Olsalazine in the treatment of mild to moderate ulcerative colitis [abstract]. Gastroenterology 1988; 84: A381Google Scholar
  105. 105.
    Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990; 85: 562–6PubMedGoogle Scholar
  106. 106.
    Yang Y. Balsalazide as salvage therapy for mesalamine failure/ intolerance in patients with ulcerative colitis. Am J Gastroenterol 2001; 90: S313–4Google Scholar
  107. 107.
    Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145–53PubMedGoogle Scholar
  108. 108.
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345–53PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Center for Inflammatory Bowel Disease, Division of Gastroenterology, Rabb/Rose 1Harvard Medical School, Beth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations